Identification of cartilage oligomeric matrix protein as biomarker predicting abatacept response in rheumatoid arthritis patients with insufficient response to a first anti-TNFα treatment
This study was funded by Bristol-Myers Squibb. Proteomics investigations benefited from grants from the “Investissement d’Avenir Infrastructures Nationales en Biologie et Santé” program (ProFI project, ANR-10-INBS-08).
Role of the funding source
Data collection, data analysis, data interpretation, manuscript preparation, decision to publish were independent from the study funding.
Authors’ contributions
PG, AB participated in the study design and coordination, and critically revised the manuscript. MVCN participated in the study design and coordination of the samples dosages, analyzed the data and drafted the manuscript. AA coordinated and performed proteomic analysis and revised the manuscript. CT helped for the samples dosages, and critically revised the manuscript. JEG supplied patient samples, collected clinical data, and revised the manuscript.
Disclosure of interest
AB and PG are co-founders of Sinnovial Company. MVCN is employee of Sinnovial Company.
Annie Adrait and Candice Trocme declare that they have no competing interest. Dr Gottenberg reported receiving grant support from Abbvie, Pfizer, and Roche and personal fees from Bristol-Myers Squibb, Merck, Sharp, and Dohme, UCB, GlaxoSmithKline, and Novartis.
Acknowledgments
We thank the patients and staff members who participated in this study and particularly Sylvie Papacatzis, Dr Federica Defendi and Dr Mohamed Habib for technical help in the quantification of biomarkers’ concentration; Floriane Pailleux and Aude Durand for technical help in the proteomic experiments and Yohann Couté and Virginie Brun for the analysis, input and discussion in the proteomic experiments as well as in the manuscript drafting; Anaïs Courtier for her implication in the study design,
References (6)
JS Smolen et al.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs
Ann Rheum Dis
(2017)
C Salliot et al.
Indirect comparisons of the efficacy of biological anti-rheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying anti-rheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis
Ann Rheum Dis
(2011)
R Rendas-Baum et al.
Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors
Arthritis Res Ther
(2011)
There are more references available in the full text version of this article.
